

Remarks

The specification has been amended to insert sequence identifiers for the various sequence listings.

Claims 1, 7, 9, 12 to 14, 16, 21, 23 to 25, 28 to 29, 33 and 39 have been amended to correct inadvertent typographical errors and to comport the claims with U.S. claim format.

Claims 1 and 12 have been amended to include prodrugs of the compounds. Support for these amendments can be found, for example, on page 17, lines 12 to 24 of the specification and in original claims 28 and 29.

Claims 32 to 36 have been amended to clarify that these claims refer to methods of treatment. Support for these amendments can be found, for example, on page 19, lines 9 to 24 of the specification.

No new matter has been added by these amendments. As presently amended, claims 1 to 42 are pending in this application.

A sequence listing has been added to the present application. The sequences can be found in the specification as filed, for example, on pages 22 to 28. No new matter has been added.

Entry of the foregoing amendments and consideration of the remarks are respectfully requested.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

June 25, 2007

Date

sanofi-aventis US LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8995
Telefax (908) 231-2626
Sanofi-Aventis Docket No. FRAV2003/0004 US NP

Kelly L. Bender

Kelly L. Bender, Reg. No. 52,610
Attorney for Applicant